Billiontoone Inc(BLLN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:30 PM ET (Korea 9/11 08:30)
Full metrics table
| Index | - | P/E | 159.89 | EPS (ttm) | 0.62 | Insider Own | 49.24% | Shs Outstand | 42.3M | Perf Week | 2.45% |
| Market Cap | 4.65B | Forward P/E | 94.85 | EPS next Y | 31.23% | Insider Trans | -1.19% | Shs Float | 23.9M | Perf Month | 0.58% |
| Enterprise Value | 4.24B | PEG | 0.71 | EPS next Q | 0.15 | Inst Own | 28.86% | Short Float | 8.14% | Perf Quarter | -0.76% |
| Income | 0.03B | P/S | 11.7 | EPS this Y | 465.31% | Inst Trans | 4.72% | Short Ratio | 2.67 | Perf Half Y | 46.24% |
| Sales | 0.40B | P/B | 8.59 | EPS next 5Y | 132.78% | ROA | 6.13% | Short Interest | 1.95M | Perf YTD | 20.37% |
| Book/sh | 11.46 | P/C | 8.47 | EPS past 3/5Y | - | ROE | 9.05% | 52W High | -34.52% ($150.44) | Perf Year | - |
| Cash/sh | 11.63 | P/FCF | 140.14 | Sales past 3/5Y | 106.24% - | ROIC | 4.74% | 52W Low | 58.99% ($61.96) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 76.33 | EPS Y/Y TTM | 201.39% | Gross Margin | 71.27% | Volatility(W/M) | 5.56% 4.99% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 10.68 | Sales Y/Y TTM | 90.12% | Oper. Margin | 10.9% | ATR (14) | 6.01 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.31 | EPS Q/Q | 2789.09% | Profit Margin | 8.04% | RSI (14) | 46.33 | Recom | 1.44 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.69 | Sales Q/Q | 64.4% | SMA20 | 3.29% ($95.37) | Beta | - | Target Price | $119.75 |
| Payout | - | Debt/Eq | 0.27 | Earnings | 2026/8/5 | SMA50 | -12.46% ($112.53) | Rel Volume | 1 | Prev Close | $99.16 |
| Employees | 713 | LT Debt/Eq | 0.26 | EPS/Sales Surpr. | -18.17% 0.17% | SMA200 | 3.41% ($95.26) | Avg Volume(3M) | 0.73M | Price | $98.51 |
| IPO | 2025/11/6 | Option/Short | Yes/Yes | Trades | 10389 | Volume | 729,070 | Change | -0.66% |
Company
BLLN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A diagnostics company that leverages molecular diagnostic technology to offer prenatal testing and oncology diagnostics. Using its proprietary molecular counting technology, it provides non-invasive prenatal testing, single-gene disease screening, and liquid biopsy-based tumor diagnostics, and is growing rapidly with differentiated test accuracy. An emerging player in the prenatal and oncology diagnostics space.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
BLLN makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +465.3% this year.
Tap to view numbers
The price looks about right
Trading at 159.9 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 28.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
LFSC 0.03%
GNOM 0.02%
XHS 0.01%
AIMS 0.00%
TNXT 0.00%It ranks #4 in the industry
Based on market cap of $5B.
BLLN $5B PER 159.9
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is BLLN?
BLLN belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of BLLN?
The market cap of BLLN is approximately $4.6B, ranking 1,439 within its sector.
What is the P/E ratio of BLLN?
BLLN has a P/E ratio of approximately 159.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BLLN?
BLLN has recorded a 52-week high of $150.44 and a low of $61.96.
